Predictive value of pharmacokinetics-adjusted phenotypic susceptibility on response to ritonavir-enhanced protease inhibitors (PIs) in human immunodeficiency virus-infected subjects failing prior PI therapy

Predictive value of pharmacokinetics-adjusted phenotypic susceptibility on response to ritonavir-enhanced protease inhibitors (PIs) in human immunodeficiency virus-infected subjects failing prior PI therapy

Item

http://www.wikidata.org/entity/Q37204276

Q37204276

about

Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data.Barriers to antiretroviral therapy adherence and plasma HIV RNA suppression among AIDS clinical trials group study participants HIV-1 protease inhibitors and clinical malaria: a secondary analysis of the AIDS Clinical Trials Group A5208 study Lower CD4 cell count and higher virus load, but not antiretroviral drug resistance, are associated with AIDS-defining events and mortality: an ACTG Longitudinal Linked Randomized Trials (ALLRT) analysis.Peripheral neuropathy in ART-experienced patients: prevalence and risk factors

P2860

Q30564087-5CD265B0-94E2-4C20-AA19-EB5E40BF1FF7 Q35156644-E00C45EA-6E96-48C8-9C61-33418CEC3775 Q35689395-0CA8C0E8-8874-490A-B650-35334B067150 Q35872395-78791ED5-909A-40B9-85D9-B9AFB9458EFC Q37662415-863F7E46-AD6E-4CBB-AD96-02934F54A417

P2860

Predictive value of pharmacokinetics-adjusted phenotypic susceptibility on response to ritonavir-enhanced protease inhibitors (PIs) in human immunodeficiency virus-infected subjects failing prior PI therapy

Item

http://www.wikidata.org/entity/Q37204276

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 23 March 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Predictive value of pharmacoki ...... jects failing prior PI therapy

@en

Predictive value of pharmacoki ...... r-enhanced protease inhibitors

@nl

type

Item

label

Predictive value of pharmacoki ...... jects failing prior PI therapy

@en

Predictive value of pharmacoki ...... r-enhanced protease inhibitors

@nl

prefLabel

Predictive value of pharmacoki ...... jects failing prior PI therapy

@en

Predictive value of pharmacoki ...... r-enhanced protease inhibitors

@nl

P1476

Predictive value of pharmacoki ...... jects failing prior PI therapy

@en

P2093

ACTG5126 Study Team

http://www.w3.org/2001/XMLSchema#string

Barbara Bastow

http://www.w3.org/2001/XMLSchema#string

Douglas D Richman

http://www.w3.org/2001/XMLSchema#string

Francesca Aweeka

http://www.w3.org/2001/XMLSchema#string

Gary E Pakes

http://www.w3.org/2001/XMLSchema#string

Hulin Wu

http://www.w3.org/2001/XMLSchema#string

Jeong-Gun Park

http://www.w3.org/2001/XMLSchema#string

Richard Haubrich

http://www.w3.org/2001/XMLSchema#string

Song Yu

http://www.w3.org/2001/XMLSchema#string

P2860

Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug r

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.

Predictive values of the human immunodeficiency virus phenotype and genotype and of amprenavir and lopinavir inhibitory quotients in heavily pretreated patients on a ritonavir-boosted dual-protease-inhibitor regimen.

Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients.

In vivo effect of alpha(1)-acid glycoprotein on pharmacokinetics of amprenavir, a human immunodeficiency virus protease inhibitor.

Pharmacokinetic and safety evaluation of high-dose combinations of fosamprenavir and ritonavir.

Kaletra (lopinavir/ritonavir).

Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients.

Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients

Interpretation of genotype and pharmacokinetics for resistance to fosamprenavir-ritonavir-based regimens in antiretroviral-experienced patients

P304

2335-2341

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.01387-08

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Joseph J Eron

P577

2009-03-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19307363

http://www.w3.org/2001/XMLSchema#string

P932

2687257

http://www.w3.org/2001/XMLSchema#string

Predictive value of pharmacokinetics-adjusted phenotypic susceptibility on response to ritonavir-enhanced protease inhibitors (PIs) in human immunodeficiency virus-infected subjects failing prior PI therapy

about

P2860

P2860

Predictive value of pharmacokinetics-adjusted phenotypic susceptibility on response to ritonavir-enhanced protease inhibitors (PIs) in human immunodeficiency virus-infected subjects failing prior PI therapy

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932